You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3)
|
|---|---|
| Published in |
Diabetes Technology & Therapeutics, April 2018
|
| DOI | 10.1089/dia.2017.0363 |
| Pubmed ID | |
| Authors |
Arndís F. Ólafsdóttir, William Polonsky, Jan Bolinder, Irl B. Hirsch, Sofia Dahlqvist, Hans Wedel, Thomas Nyström, Magnus Wijkman, Erik Schwarcz, Jarl Hellman, Tim Heise, Marcus Lind |
| Abstract |
To evaluate the effects of continuous glucose monitoring (CGM) on nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with multiple daily insulin injections (MDI); we also evaluated factors related to differences in hypoglycemia confidence in this population. Evaluations were performed from the GOLD randomized trial, an open-label multicenter crossover randomized clinical trial (n = 161) over 69 weeks comparing CGM to self-measurement of blood glucose (SMBG) in persons with type 1 diabetes treated with MDI. Masked CGM and the hypoglycemia confidence questionnaire were used for evaluations. Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001). For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively. Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020). Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033) and indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022). CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life. ClinicalTrials.gov , number NCT02092051. |
X Demographics
The data shown below were collected from the profiles of 46 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 19 | 41% |
| Spain | 3 | 7% |
| United States | 2 | 4% |
| Italy | 1 | 2% |
| Denmark | 1 | 2% |
| Ireland | 1 | 2% |
| Unknown | 19 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 29 | 63% |
| Practitioners (doctors, other healthcare professionals) | 9 | 20% |
| Scientists | 7 | 15% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 175 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 175 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 21 | 12% |
| Other | 15 | 9% |
| Student > Bachelor | 13 | 7% |
| Researcher | 12 | 7% |
| Student > Doctoral Student | 8 | 5% |
| Other | 28 | 16% |
| Unknown | 78 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 20% |
| Nursing and Health Professions | 29 | 17% |
| Engineering | 8 | 5% |
| Psychology | 3 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Other | 13 | 7% |
| Unknown | 84 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 April 2019.
All research outputs
#1,200,358
of 25,998,826 outputs
Outputs from Diabetes Technology & Therapeutics
#112
of 1,573 outputs
Outputs of similar age
#26,257
of 346,536 outputs
Outputs of similar age from Diabetes Technology & Therapeutics
#1
of 18 outputs
Altmetric has tracked 25,998,826 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,573 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,536 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.